Ranibizumab Treatment and Protocols in Diabetic Retinopathy and Diabetic Macular Edema

Diabetic macular edema (DME) is one of the most common causes of visual loss in patients with diabetic retinopathy (DRP). The prognosis of central involved diabetic macular edema has improved after anti-VEGF treatments. Intravitreal ranibizumab was the first anti-VEGF agent approved by the FDA for the treatment of diabetic macular edema. Despite the fact that it is a pathogenic treatment, it has brought some challenging situations on its own. In most studies, optimal dose and combined treatment were evaluated in terms of treatment efficacy. Recent studies revealed that ranibizumab treatment is effective in DRP and proliferative DRP regression as well as in diabetic macular edema treatment. In this article, we aimed to review the effects of Ranibizumab treatment on visual acuity, central macular thickness in patients with diabetic retinopathy and diabetic macular edema through studies.